Latest Insider Transactions at Laboratory Corp Of America Holdings (LH)
This section provides a real-time view of insider transactions for Laboratory Corp Of America Holdings (LH). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of LABORATORY CORP OF AMERICA HOLDINGS to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of LABORATORY CORP OF AMERICA HOLDINGS's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 02
2023
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
119
-1.67%
|
$30,226
$254.99 P/Share
|
|
Feb 02
2023
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
BUY
Exercise of conversion of derivative security
|
Direct |
443
+5.85%
|
-
|
|
Feb 02
2023
|
Amy B. Summy EVP, Chief Marketing Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
77
-16.38%
|
$19,558
$254.99 P/Share
|
|
Feb 02
2023
|
Amy B. Summy EVP, Chief Marketing Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
220
+31.88%
|
-
|
|
Feb 02
2023
|
Paul R Kirchgraber CEO, Covance Drug Development |
SELL
Payment of exercise price or tax liability
|
Direct |
141
-1.05%
|
$35,814
$254.99 P/Share
|
|
Feb 02
2023
|
Paul R Kirchgraber CEO, Covance Drug Development |
BUY
Exercise of conversion of derivative security
|
Direct |
443
+3.18%
|
-
|
|
Feb 02
2023
|
Lance Berberian EVP, Special Advisor, Strategy |
SELL
Payment of exercise price or tax liability
|
Direct |
102
-0.52%
|
$25,908
$254.99 P/Share
|
|
Feb 02
2023
|
Lance Berberian EVP, Special Advisor, Strategy |
BUY
Exercise of conversion of derivative security
|
Direct |
297
+1.48%
|
-
|
|
Feb 02
2023
|
Brian J Caveney EVP, Pres of ED, CMO & CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
144
-0.91%
|
$36,576
$254.99 P/Share
|
|
Feb 02
2023
|
Brian J Caveney EVP, Pres of ED, CMO & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
443
+2.72%
|
-
|
|
Feb 02
2023
|
Glenn A Eisenberg Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
206
-0.6%
|
$52,324
$254.99 P/Share
|
|
Feb 02
2023
|
Glenn A Eisenberg Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
767
+2.17%
|
-
|
|
Nov 08
2022
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
SELL
Open market or private sale
|
Direct |
1,116
-14.3%
|
$258,912
$232.67 P/Share
|
|
Nov 07
2022
|
Brian J Caveney EVP, Pres of ED, CMO & CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
894
-5.49%
|
$208,302
$233.77 P/Share
|
|
Nov 07
2022
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
894
-10.28%
|
$208,302
$233.77 P/Share
|
|
Nov 05
2022
|
Brian J Caveney EVP, Pres of ED, CMO & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,010
+10.98%
|
-
|
|
Nov 05
2022
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,010
+18.77%
|
-
|
|
Nov 01
2022
|
Paul R Kirchgraber CEO, Covance Drug Development |
SELL
Payment of exercise price or tax liability
|
Direct |
892
-6.41%
|
$198,024
$222.56 P/Share
|
|
Nov 01
2022
|
Paul R Kirchgraber CEO, Covance Drug Development |
BUY
Exercise of conversion of derivative security
|
Direct |
2,007
+12.6%
|
-
|
|
Nov 01
2022
|
Adam H Schechter President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
893
-4.83%
|
$198,246
$222.56 P/Share
|
|
Nov 01
2022
|
Adam H Schechter President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,007
+9.8%
|
-
|
|
Nov 01
2022
|
Glenn A Eisenberg Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
5,348
-13.65%
|
$1,187,256
$222.56 P/Share
|
|
Nov 01
2022
|
Glenn A Eisenberg Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
12,032
+23.49%
|
-
|
|
Sep 26
2022
|
Glenn A Eisenberg Executive Vice President |
SELL
Open market or private sale
|
Direct |
25,000
-14.67%
|
$5,250,000
$210.62 P/Share
|
|
Sep 07
2022
|
Brian J Caveney EVP, Pres of ED, CMO & CSO |
BUY
Open market or private purchase
|
Direct |
44
+0.31%
|
$10,164
$231.2 P/Share
|
|
Aug 03
2022
|
Glenn A Eisenberg Executive Vice President |
SELL
Open market or private sale
|
Direct |
32,100
-14.22%
|
$8,153,400
$254.13 P/Share
|
|
Aug 03
2022
|
Glenn A Eisenberg Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
32,100
+12.81%
|
$4,750,800
$148.56 P/Share
|
|
Aug 01
2022
|
Peter J Wilkinson SVP, Chief Accounting Officer |
SELL
Bona fide gift
|
Direct |
351
-14.97%
|
-
|
|
Aug 01
2022
|
Peter J Wilkinson SVP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
23
-1.19%
|
$5,911
$257.94 P/Share
|
|
Aug 01
2022
|
Peter J Wilkinson SVP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
817
+12.47%
|
$119,282
$146.59 P/Share
|
|
Aug 01
2022
|
Peter J Wilkinson SVP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
2,576
-26.0%
|
$664,608
$258.54 P/Share
|
|
Jun 07
2022
|
Brian J Caveney EVP, Pres of ED, CMO & CSO |
BUY
Open market or private purchase
|
Direct |
42
+0.3%
|
$10,164
$242.19 P/Share
|
|
Mar 29
2022
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
2,449
-31.66%
|
$678,373
$277.11 P/Share
|
|
Mar 29
2022
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
SELL
Open market or private sale
|
Direct |
2,356
-26.29%
|
$652,612
$277.11 P/Share
|
|
Mar 28
2022
|
Peter J Wilkinson SVP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
915
-19.84%
|
$252,540
$276.42 P/Share
|
|
Mar 28
2022
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,792
-18.81%
|
$494,592
$276.42 P/Share
|
|
Mar 28
2022
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,885
-17.38%
|
$520,260
$276.42 P/Share
|
|
Mar 28
2022
|
Paul R Kirchgraber CEO, Covance Drug Development |
SELL
Payment of exercise price or tax liability
|
Direct |
1,648
-12.15%
|
$454,848
$276.42 P/Share
|
|
Mar 28
2022
|
Glenn A Eisenberg Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
6,286
-10.76%
|
$1,734,936
$276.42 P/Share
|
|
Mar 28
2022
|
Brian J Caveney EVP, Pres of ED, CMO & CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,883
-11.76%
|
$519,708
$276.42 P/Share
|
|
Mar 28
2022
|
Lance Berberian EVP, Special Advisor, Strategy |
SELL
Payment of exercise price or tax liability
|
Direct |
2,360
-10.8%
|
$651,360
$276.42 P/Share
|
|
Mar 27
2022
|
Peter J Wilkinson SVP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,822
+37.97%
|
-
|
|
Mar 27
2022
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,241
+30.8%
|
-
|
|
Mar 27
2022
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
BUY
Grant, award, or other acquisition
|
Direct |
4,241
+28.11%
|
-
|
|
Mar 27
2022
|
Paul R Kirchgraber CEO, Covance Drug Development |
BUY
Grant, award, or other acquisition
|
Direct |
3,707
+21.47%
|
-
|
|
Mar 27
2022
|
Glenn A Eisenberg Executive Vice President |
BUY
Grant, award, or other acquisition
|
Direct |
14,144
+19.49%
|
-
|
|
Mar 27
2022
|
Brian J Caveney EVP, Pres of ED, CMO & CSO |
BUY
Grant, award, or other acquisition
|
Direct |
4,241
+20.94%
|
-
|
|
Mar 27
2022
|
Lance Berberian EVP, Special Advisor, Strategy |
BUY
Grant, award, or other acquisition
|
Direct |
5,310
+19.54%
|
-
|
|
Mar 25
2022
|
R Sanders Williams Director |
SELL
Open market or private sale
|
Direct |
572
-8.17%
|
$155,584
$272.98 P/Share
|
|
Mar 25
2022
|
Kathryn E Wengel Director |
BUY
Exercise of conversion of derivative security
|
Direct |
603
+50.0%
|
-
|